TECH

TECH (Bio-Techne Corporation) Analyst Note Date: 2026-06-20 Event Date: 2026-06-20

1. Structural Readiness

Conservative Entry: $68.40 Current Price: $57.94 Extension: -15.3% vs. conservative entry Breakout Level: $68.40 (Conservative)

Analysis:

2. The Thesis Layer

Primary Secular Theme: Biotech & GLP-1 → Platforms, Tools & CRO/CDMO (Tier Direct) Thesis Weighting: High Confidence

Bio-Techne operates as a direct beneficiary within the "Platforms, Tools & CRO/CDMO" tier of the Biotech & GLP-1 secular theme. The company does not manufacture the therapeutics themselves but provides the foundational "picks and shovels" required for the development and manufacturing of advanced therapeutics, including cell therapies and antibody drug conjugates (ADCs).

The conviction in this thesis is supported by the company's dual-segment structure:

• Protein Sciences: The larger segment (72% of FY2025 revenue), providing essential reagents (cytokines, growth factors, antibodies) for bioprocessing.
• Diagnostics and Spatial Biology: The growth engine (28% of FY2025 revenue), offering spatial biology and liquid biopsy tools.

The thesis is further reinforced by the structural tailwind of AI adoption in drug discovery. Management explicitly views the demand for content-rich biological datasets as a durable tailwind for their spatial biology and proteomic platforms, positioning the company to benefit from the expansion of viable drug programs driven by AI.

3. The Business

Business Model & Industry: Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates in the Healthcare sector, specifically within the Life Sciences Tools & Services industry.

Operational Evidence (as of 2026-06-20):

• Segment Performance: The Protein Sciences segment remains the revenue anchor, representing approximately 72% of net sales in fiscal 2025. The Diagnostics and Spatial Biology segment, representing 28% of net revenues, includes three divisions focused on diagnostic and research markets.
• Growth Drivers: In the quarter ended May 2026, the Spatial Biology portfolio delivered mid-teens growth. Management reported a record backlog for the COMET platform, positioning the platform for continued growth. Excluding the impact of two specific customers, GMP protein revenue grew nearly 50% year-over-year.
• Product Innovation: The company introduced over 400 new products in fiscal 2025, demonstrating an ability to keep pace with changing technologies.
• Geographic Demand: Management noted increasing demand in China from biopharma and CRO customers focused on ADCs, cell therapy, and autoimmune disorders.
• Financial Structure: As of March 31, 2026, the outstanding balance under the Credit Agreement was $200.0 million, down from $346.0 million as of June 30, 2025, indicating active deleveraging.
• Strategic Agreements: The company holds a contract with Wilson Wolf, where the second part of the agreement could be accelerated if Wilson Wolf meets a milestone of approximately $226 million in annual revenue or $136 million in annual EBITDA by December 31, 2027. Additionally, a promissory note with a buyer matures in September 2029, requiring four annual installments of $2.5 million.

4. Archetype and Conviction

Archetype: Quality Compounder Fit Analysis: Bio-Techne fits the Quality Compounder archetype due to its dominant market position in essential reagents, high barriers to entry in spatial biology, and consistent product innovation (400+ new products in FY2025). The company generates cash flow to support R&D and strategic acquisitions while maintaining a strong balance sheet.

Conviction Stack:

• Thesis Strength: High. The company is a direct, tier-1 beneficiary of the biotech infrastructure build-out.
• Evidence Quality: Strong. Recent earnings (May 2026) confirm record backlogs and double-digit growth in key segments.
• Structural Quality: Moderate to High. The ATR at the time of the attempted breakout was 3.1% (productive), but the current ATR is 4.0% (high), suggesting elevated volatility.

Valuation Context: Management expects organic growth in the fourth quarter to be approximately flat. This guidance, combined with the high current volatility (4.0% ATR), suggests a period of consolidation or re-rating is necessary before the next structural move.

5. Invalidating Factors, Strengthening Factors, and Gaps

Invalidating Factors:

• Fundamental: A significant contraction in the COMET platform backlog or a failure to meet the Wilson Wolf revenue milestones could dampen the growth narrative.

Strengthening Factors:

• Fundamental: Continued acceleration in GMP protein revenue (currently +50% ex-two customers) and expansion of the Spatial Biology backlog.

Gaps in Evidence:

• Missing Evidence: There is no specific evidence in the provided block regarding the *current* quarter's (Q2 2026) specific revenue guidance or the exact timing of the next earnings release relative to the June 20 date.
• Missing Evidence: No explicit data on the *current* gross margin percentage for the Spatial Biology segment, only revenue growth rates.
• Missing Evidence: No specific data on the *current* cash conversion cycle or working capital changes beyond the credit agreement balance.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: Record backlog for COMET platform; GMP protein revenue grew nearly 50% year-over-year excluding two customers; Credit agreement balance reduced to $200.0 million from $346.0 million. Expected path: Management expects the COMET platform to drive continued growth; the company is actively deleveraging; the stock may consolidate to retest support levels before a new structural move. Expected horizon: 3 to 6 months for the technical structure to re-form or for fundamental catalysts to drive a new breakout. Failure mode to watch: A sustained close below the current price levels ($57.94) indicating a breakdown in the broader support structure, potentially signaling a deeper correction.